![]() |
ИСТИНА |
Войти в систему Регистрация |
ФНКЦ РР |
||
A relatively new and promising area of research in nuclear medicine is the development of biocompatible nanomaterials labelled with radionuclides for the early diagnosis and effective treatment of oncological diseases. Nanoparticles are a convenient platform for creating combined radiopharmaceuticals. At the same time, nanomaterials themselves often have interesting properties for biomedicine. Nanosized cerium dioxide is of interest as a potential component of radiopharmaceuticals, since it has antioxidant properties, which allow it to be used as a radioprotector to minimize the damage of ionizing radiation to healthy organs and tissues. At the same time, in malignant neoplasms, cerium dioxide shows prooxidant properties, which will potentially enhance the therapeutic effect of the administered drug. At the same time, due to pH sensitivity, cerium oxide exhibits vector properties and is able to deliver the drug to the affected tissue. Thus, the aim of this work is to obtain novel conjugates of cerium oxide nanoparticles with DOTA and azacrown ligand with 6 nitrogen heteroatoms in the macrocycle (ligand L that was previously studied with both bismuth [1] and zinc [2] radionuclides) and to analyze their labelling with Bi-207 and Zn-65, as well as in vitro and in vivo stability.
№ | Имя | Описание | Имя файла | Размер | Добавлен |
---|---|---|---|---|---|
1. | Полный текст | s41181-023-00193-4_2IovxYs.pdf | 1,1 МБ | 21 июня 2023 [glebkms] | |
2. | s41181-023-00193-4.pdf | s41181-023-00193-4.pdf | 1,1 МБ | 21 июня 2023 [glebkms] |